Examples of promising HIF-hydroxylase inhibitors are GKS-1278863, FG-4592, and AKB-6548, all of which increase circulating erythropoietin and help to alleviate anemia in these patients [reviewed by Haase (2017)]. Here, EPO is linked to anemia.